Discovery of tetrahydroisoquinoline-based bivalent heterodimeric IAP antagonists

https://doi.org/10.1016/j.bmcl.2014.09.022Get rights and content

Abstract

Bivalent heterodimeric IAP antagonists that incorporate (R)-tetrahydroisoquinoline in the P3′ subunit show high affinity for the BIR2 domain and demonstrated potent IAP inhibitory activities in biochemical and cellular assays. Potent in vivo efficacy was observed in a variety of human tumor xenograft models. The bivalent heterodimeric molecule 3 with a P3–P3′ benzamide linker induced pharmacodynamic markers of apoptosis and was efficacious when administered intravenously at a dose of 1 mg/kg to mice harboring A875 human melanoma tumors. Analog 5, with a polyamine group incorporated at the P2′ thiovaline side chain exhibited antiproliferative activity against the P-gp expressing HCT116/VM46 cell line.

References and notes (32)

  • S. Inoue et al.

    Cell Death Differ.

    (2009)
  • C. Du et al.

    Cell

    (2000)
    A.M. Verhagen et al.

    Cell

    (2000)
  • T.K. Oost et al.

    J. Med. Chem.

    (2004)
    S. Fulda et al.

    Nat. Rev.

    (2012)
  • P.J. Jost et al.

    Nature

    (2009)
  • A.T. Wright et al.

    J. Am. Chem. Soc.

    (2009)
  • M.A. Poss et al.

    Synth. Commun.

    (1993)
    K.S. Kim et al.

    Tetrahedron Lett.

    (1993)
  • G. Wu et al.

    Chem. Biol.

    (2003)
  • S. Xie et al.

    Expert Opin. Drug Deliv.

    (2010)
  • H. Steller

    Science

    (1995)
    D. Hanahan et al.

    Cell

    (2011)
  • S. Fulda et al.

    Nat. Rev. Drug Disc.

    (2012)
    S. Condon

    Ann. Rep. Med. Chem.

    (2011)
  • G.S. Salvesen et al.

    Nat. Rev. Mol. Cell Biol.

    (2002)
  • Q.L. Deveraux et al.

    Genes Dev.

    (1999)
  • B.P. Eckelman et al.

    J. Biol. Chem.

    (2006)
  • B.P. Eckelman et al.

    EMBO Rep.

    (2006)
  • R.A. Kipp et al.

    Biochemistry

    (2002)
    Z. Liu et al.

    Nature

    (2000)
  • A.D. Wist et al.

    Bioorg. Med. Chem.

    (2007)
  • Cited by (14)

    • Targeting estrogen receptor α for degradation with PROTACs: A promising approach to overcome endocrine resistance

      2020, European Journal of Medicinal Chemistry
      Citation Excerpt :

      All examples shown in Fig. 14 possess ERα degradation activity at 1 μM concentration. In 2016, GSK patented the other kind of PROTAC compounds incorporating IAP recruiting moiety [140] and raloxifene derivative [141,142]. These PROTACs displayed >50% ERα degradation at concentrations lower than 1 μM (Fig. 15).

    • Mapping the substrate scope of monoamine oxidase (MAO-N) as a synthetic tool for the enantioselective synthesis of chiral amines

      2018, Bioorganic and Medicinal Chemistry
      Citation Excerpt :

      A variety of strategies such as diastereomeric resolution, homogeneous catalysis or biocatalytic approaches have been reported for the preparation of chiral amines.7 The use of biocatalysis has grown remarkably in the past decades as exemplified by the use of ω-transaminases,8 phenylalanine ammonia lyases,9 amine dehydrogenases10 and imine reductases.11 An attractive alternative to the kinetic resolution of amines involves the use of monoamine oxidase, an enzyme class which only requires aerial oxygen with no need for additional or sacrificial co-factors.12

    • Building homogeneous time-resolved fluorescence resonance energy transfer assays for characterization of bivalent inhibitors of an inhibitor of apoptosis protein target

      2016, Analytical Biochemistry
      Citation Excerpt :

      Bivalent Smac-mimetic ligands are expected to mimic the mode of action of the mature dimeric Smac protein in its interaction with XIAP. Thus, it is not surprising that, in our current and previous studies [17,18,23], bivalent Smac-mimetics that bind concurrently to both the BIR2 and BIR3 domains of XIAP achieve much higher affinities than do the corresponding monovalent analogs. Bivalent Smac-based ligands were also much more potent antagonists of XIAP compared with the corresponding monovalent Smac-based ligands in cell proliferation and cell-free caspase functional assays.

    • Pharmacology of smac mimetics; chemotype differentiation based on physical association with caspase regulators and cellular transport

      2015, Experimental Cell Research
      Citation Excerpt :

      Inhibition data was calculated from average reaction rate values generated by using a proprietary XIAP BIR2-3 antagonist at 20 µM and a vehicle-only reaction for 100% and 0% inhibition respectively Assays were performed in 96 well plates as described [32]. Briefly, cells were seeded on day zero at a concentration enabling continuous log growth over the course of the assay.

    View all citing articles on Scopus
    View full text